Reimagining pain relief
Pain is personal, so pain care should be personalized. Our therapies support patients by addressing pain locally through prolonged mechanisms of action, offering safe alternatives to opioids when and where they’re needed most.
Take control of your recovery
Our portfolio of non-opioid solutions provides targeted relief for every stage of recovery, supporting your unique needs and empowering you to manage pain effectively. See if a non-opioid option is right for you.
These products have not been studied together in clinical trials. See important safety information for EXPAREL, ZILRETTA and ioveraº.
Therapeutic specialties
Musculoskeletal pain
Orthopedic surgery and chronic musculoskeletal conditions often lead to ongoing pain, challenging patients’ mobility, independence, and quality of life. Traditional pain management options often include opioids, which carry side effects, long-term risks and may fall short of delivering sustainable relief. Non-opioid solutions provide effective, targeted pain control that promotes recovery after surgery and empowers patients with lasting relief from chronic orthopedic conditions.
For patients, non-opioid options mean reduced side effects, enhanced mobility, and a more active role in recovery and pain management. For healthcare providers, these solutions represent an opportunity to support healing, lower the reliance on opioids, and improve long-term orthopedic outcomes. By advancing non-opioid pain relief in orthopedics, this approach helps set a new standard in supporting safe, sustainable recovery and better patient care.
Acute postsurgical pain
Patients are often prescribed a high number of opioids to manage their postsurgical pain, which puts them at risk for side effects that can slow recovery, chronic opioid use, or leftover prescriptions stored unsafely in their homes. Non-opioid solutions provide safer, effective, and more sustainable pain relief across a variety of surgical procedures while reducing the risks associated with opioid overprescribing.
For patients, this approach can lead to faster recovery times, fewer complications, and an overall better postsurgical experience. For physicians, non-opioid solutions present an opportunity to enhance patient care by minimizing opioid-related challenges, offering more tailored pain management, and supporting long-term health outcomes. This innovation empowers both patients and healthcare providers to prioritize recovery and quality of life, setting a new standard for postsurgical pain relief.
Chronic pain
Chronic pain can disrupt nearly every part of daily life—from the ability to move freely at home to getting a restful night’s sleep and staying productive at work. Non-opioid pain management solutions prioritize safety and quality of life by reducing the risks associated with long-term opioid use while delivering consistent pain relief directly to affected joints.
For patients, this means improved mobility, fewer disruptions to daily activities, and a more proactive approach to managing chronic pain. For healthcare providers, it offers an effective alternative to traditional pain management methods, enabling more precise treatment while minimizing the potential for opioid dependency. By focusing on sustainable pain relief, this approach supports better patient outcomes and aligns with a broader shift toward safer, more responsible pain management practices.
Better
is Possible.
A world without overreliance on opioids
While we’ve been able to provide new solutions, we know our work is not yet done. We are continuing to transform the patient journey through innovative, safe, and effective pain management options, envisioning a future without overreliance on opioids.
Our strong foundation enables us to invest in groundbreaking pain management therapies, expanding our ability to transform more lives. Learn more about our in-development products.
Our strategy has also never been solely about our products. Learn more about how we’re putting our mission into action by equipping patients and providers with the information needed to transform care.
Important safety information
Indications
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.
Important safety information
- EXPAREL is contraindicated in obstetrical paracervical block anesthesia.
- Adverse reactions reported in adults with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported in adults with an incidence greater than or equal to 10% following EXPAREL administration via nerve block were nausea, pyrexia, headache, and constipation.
- Adverse reactions with an incidence greater than or equal to 10% following EXPAREL administration via infiltration in pediatric patients six to less than 17 years of age were nausea, vomiting, constipation, hypotension, anemia, muscle twitching, vision blurred, pruritus, and tachycardia.
- Do not admix lidocaine or other non-bupivacaine local anesthetics with EXPAREL. EXPAREL may be administered at least 20 minutes or more following local administration of lidocaine.
- EXPAREL is not recommended to be used in the following patient populations: patients <6 years old for infiltration, patients younger than 18 years old for nerve blocks, and/or pregnant patients.
- Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease.
Warnings and precautions specific to EXPAREL
- Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL.
- EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks other than interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and adductor canal block, or intravascular or intra-articular use.
- The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days, as seen in clinical trials.
Warnings and precautions for bupivacaine-containing products
- Central Nervous System (CNS) Reactions: There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression.
- Cardiovascular System Reactions: Toxic blood concentrations depress cardiac conductivity and excitability, which may lead to dysrhythmias, sometimes leading to death.
- Allergic Reactions: Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients.
- Chondrolysis: There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use.
- Methemoglobinemia: Cases of methemoglobinemia have been reported with local anesthetic use.
For more information, view prescribing information
Indication
The iovera° system is used to destroy tissue during surgical procedures by applying freezing cold. It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain. It is also indicated for the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days. The iovera° system is not indicated for treatment of central nervous system tissue.
When stimulation compatible components are used, the iovera° system can also facilitate target nerve location by conducting electrical nerve stimulation from a compatible 3rd party nerve stimulator.
Important safety information
Contraindications
The iovera° system is contraindicated for use in patients with the following:
- Cryoglobulinemia, paroxysmal cold hemoglobinuria, cold urticaria, Raynaud’s disease, and open and/or infected wounds at or near the treatment site
Potential complications
As with any surgical treatment that uses needle-based therapy and local anesthesia, there is a potential for site-specific reactions, including, but not limited to:
- Ecchymosis, edema, erythema, local pain and/or tenderness, and localized dysesthesia
Proper use of the device as described in the User Guide can help reduce or prevent the following complications:
- At the treatment site(s): injury to the skin related to application of cold or heat, hyper- or hypopigmentation, and skin dimpling
- Outside the treatment site(s): loss of motor function
Indications
ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.
Limitation of Use: The efficacy and safety of repeat administration of ZILRETTA have not been demonstrated.
Contraindication
ZILRETTA is contraindicated in patients who are hypersensitive to triamcinolone acetonide, corticosteroids, or any components of the product.
Warnings and precautions for bupivacaine-containing products
- Intra-articular Use Only: ZILRETTA has not been evaluated and should not be administered by epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, or subcutaneous routes. Serious events have been reported with epidural and intrathecal administration of corticosteroids and none are approved for this use. ZILRETTA should not be considered safe for epidural or intrathecal administration.
- Hypersensitivity Reactions: Rare instances of anaphylaxis, including serious cases, have occurred in patients with hypersensitivity to corticosteroids.
- Joint Infection and Damage: A marked increase in pain accompanied by local swelling, restriction of joint motion, fever, and malaise are suggestive of septic arthritis. Examine joint fluid to exclude a septic process. If diagnosis is confirmed, institute appropriate antimicrobial therapy. Avoid injecting corticosteroids into a previously infected or unstable joint. Intra-articular administration may result in damage to joint tissues.
- Increased Risk of Infections: Infection with any pathogen in any location of the body may be associated with corticosteroid use. Corticosteroids may increase the susceptibility to new infection and decrease resistance and the ability to localize infection.
- Alterations in Endocrine Function: Corticosteroids can produce reversible hypothalamic-pituitary-adrenal axis suppression, with potential for adrenal insufficiency after withdrawal of treatment, which may persist for months. In situations of stress during that period, institute corticosteroid replacement therapy.
- Cardiovascular and Renal Effects: Corticosteroids can cause blood pressure elevation, salt and water retention, and increased potassium excretion. Monitor patients with congestive heart failure, hypertension, and renal insufficiency for edema, weight gain, and electrolyte imbalance. Dietary salt restriction and potassium supplementation may be needed.
- Increased Intraocular Pressure: Corticosteroid use may be associated with increased intraocular pressure. Monitor patients with elevated intraocular pressure for potential treatment adjustment.
- Gastrointestinal Perforation: Corticosteroid administration may increase risk of gastrointestinal perforation in patients with certain GI disorders and fresh intestinal anastomoses. Avoid corticosteroids in these patients.
- Alterations in Bone Density: Corticosteroids decrease bone formation and increase bone resorption. Special consideration should be given to patients with or at increased risk of osteoporosis prior to treatment.
- Behavior and Mood Disturbances: Corticosteroids may cause adverse psychiatric reactions. Prior to treatment, special consideration should be given to patients with previous or current emotional instability or psychiatric illness. Advise patients to immediately report any behavior or mood disturbances.
Adverse reactions
The most commonly reported adverse reactions (incidence ≥1%) in clinical studies included sinusitis, cough, and contusions.
For more information, view prescribing information